参考文献

参考文献

［1］Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin, 2018, 68(6): 394-424.

［2］Zhang L, Wang H, Li Q, et al.Big data and medical research in China［J］.BMJ, 2018, 360: j5910.

［3］卫生部，国家中医药管理局.电子病历基本架构与数据标准（试行）［S/OL］.http：//www.nhc.gov.cn/mohwsbwstjxxzx/s8553/200912/45414.shtml.

［4］中国抗癌协会血液肿瘤专业委员会，中华医学会血液学分会白血病淋巴瘤学组.中国成人急性淋巴细胞白血病诊断与治疗指南（2016年版）［J］.中华血液学杂志，2016，37（10）：837-845.

［5］中华医学会血液学分会白血病淋巴瘤学组.成人急性髓系白血病（非急性早幼粒细胞白血病）中国诊疗指南（2017年版）［J］.中华血液学杂志，2017，38（3）：177-182.

［6］美国东部肿瘤协助组.体能状态评分ECOG评分法［J］.中华普通外科文献：电子版，2012，6（6）：556.

［7］Liu HD, Ahn KW, Hu ZH, et al.Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia［J］.Biol Blood Marrow Transplant, 2017, 23(5): 767-775.

［8］Arber DA, Orazi A, Hasserjian R, et al.The 2016 revision to the World Health Organization classification of myeloid neoplasmas and acute leukemia［J］.Blood.2016, 127(20): 2391-2405.

［9］Acute myeloid leukemia, version 3.2019, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw, 2019, 17(6): 721-749.

［10］Chronic myeloid leukemia,version 1.2019, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw, 2018, 16(9): 1108-1135.

［11］NCCN guidelines insights: acute lymphoblastic leukemia, version 1.2017.J Natl Compr Canc Netw, 2017, 15(9): 1091-1102.

［12］Wang Y, Chen H, Chen J, et al.The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China［J］.Cancer Lett, 2018, 438: 63-75.Doi: 10.1016/j.canlet.2018.08.030.

［13］Dholaria B, Savani BN, Labopin M, et al.Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT［J］.Haematologica, 2020, 105(1): 47-58.Doi: 10.3324/haematol.2019.219790.

［14］Ljungman P, de la Camara R, Robin C, et al.Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)［J］.Lancet Infect Dis, 2019, 19(8): e260-e272.Doi: 10.1016/S1473-3099(19)30107-0.(https://www.daowen.com)

［15］Ullmann AJ, Schmidt-Hieber M, Bertz H, et al.Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.Ann Hematol, 2016 , 95(9): 1435-1455.Doi: 10.1007/s00277-016-2711-1.

［16］Dignan FL, Wynn RF, Hadzic N, et al.BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.Br J Haematol, 2013, 163(4): 444-457.Doi: 10.1111/bjh.12558.

［17］Przepiorka D, Weisdorf D, Martin P, et al.1994 consensus conference on acute GVHD grading［J］.Bone Marrow Transplant , 1995, 15(6): 825-828.

［18］Jagasia MH, Greinix HT, Arora M, et al.National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus- host disease: I.The 2014 diagnosis and staging working group report［J］.Biol Blood Marrow Transplant, 2015, 21(3): 389-401.e1.Doi: 10.1016/ j.bbmt.2014.12.001.

［19］van Esser JW, Niesters HGM, Holt Bvd, et al.Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation［J］.Blood, 2002, 99(12): 4364-4369.

［20］Dierickx D, Tousseyn T, Gheysens O.How I treat posttransplant lymphoproliferative disorders［J］.Blood, 2015, 126(20): 2274-2283.

［21］中华人民共和国卫生部.WS 370-2012卫生信息基本数据集编制规范［S］.北京：中国标准出版社，2012.

［22］北京协和医院世界卫生组织国家分类家族合作中心编译.疾病和有关健康问题的国际统计分类第十次修订本（ICD-10）［M］.北京：人民卫生出版社，2020.

［23］Dolin RH, Alschuler L, Boyer S, et al.HL7 Clinical Document Architecture［J］2nd ed.J Am Med Inform Assoc, 2006, 13(1): 30-39.Doi: 10.1197/jamia.M1888.

［24］中华医学会血液学分会.骨髓增生异常综合征中国诊断与治疗指南（2019年版）［J］.中华血液学杂志，2019，40（2）：89-97.

［25］中华医学会血液学分会红细胞疾病（贫血）学组.再生障碍性贫血诊断与治疗中国专家共识（2017年版）［J］.中华血液学杂志，2017，38（1）：1-5.

［26］中华医学会血液学分会干细胞应用学组.中国异基因造血干细胞移植治疗血液系统疾病专家共识（Ⅰ）——适应证、预处理方案及供者选择（2014年版）［J］.中华血液学杂志，2014，35（8）：775-780.

［27］中华医学会血液学分会干细胞应用学组.中国异基因造血干细胞移植治疗血液系统疾病专家共识（Ⅱ）——移植后白血病复发（2016年版）［J］.中华血液学杂志，2016，37（10）：846-851.

［28］中华医学会血液学分会干细胞应用学组.中国异基因造血干细胞移植治疗血液系统疾病专家共识（Ⅲ）——急性移植物抗宿主病（2020年版）［J］.中华血液学杂志，2020，41（07）：529-536.